Bristol-Myers Squibb Company Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (63)

Latest Posts

About This Stock More About This Stock
Week In Review: China Life Science Deals Total $550 Million
Article By: ChinaBio® Today
Saturday, December 9, 2017 4:13 PM EST
Pfizer (NYSE: PFE​) signed a $226 million agreement for China/Asian rights to Cresemba® (isavuconazole), an antifungal drug and Everest Medicines announced a $224 million partnership with San Diego's Arena Pharma.
In this article: JNJ, GNBT, BYSI, BMY, ARNA, BABA, PFE
Read
Bristol-Myers Rises After Merck Pulls Cancer Drug Combo Filing In Europe
Article By: The Fly
Monday, October 30, 2017 1:48 PM EST
Shares of Bristol-Myers Squibb are on the rise after competitor Merck announced it is withdrawing its European application for a combination regimen featuring Keytruda, the company's cancer immunotherapy drug.
In this article: BMY Also: MRK, PFE, RHHBY
Read
Bristol-Myers (BMY) Misses On Q3 Earnings, Opdivo In Focus
Article By: Zacks Investment Research
Thursday, October 26, 2017 3:12 PM EST
Bristol-Myers Squibb Company’s third-quarter 2017 earnings of 75 cents per share fell short of the Zacks Consensus Estimate as well as the year-ago quarter earnings of 77 cents.
In this article: BMY Also: CLVS, EXEL, ABBV
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich
Friday, September 29, 2017 7:25 PM EST
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Northwest Biotherapeutics, Bristol-Myers Squibb: Success For The Yervoy-Opdivo Combination
Article By: SmithOnStocks
Thursday, September 7, 2017 10:29 AM EST
The stoppage at an interim analysis of Bristol-Myers Squibb’s’ Checkmate-214 trial provides meaningful information into assessing the potential for success of Northwest Biotherapeutics.
In this article: BMY, NWBO
Read

PARTNER HEADLINES

Latest Tweets for $BMY

No tweets yet!

$BMY

OncoSec Raising Its Profile In Fight Against Cancer
Dick Kaplan 9/6/2017 4:03:09 PM

Very impressed with the #OncosSec trial results. $ONCS $MRK $BMY

1 to 1 of 1 comments